Opportunities for nanomaterials in enzyme therapy
Journal of Controlled Release · 2024-08 · 372 · 619-647
DOI: 10.1016/j.jconrel.2024.06.035 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2024-08. Verfasst von Beatriz Torres-Herrero und 5 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC/Universidad de Zaragoza, c/ Edificio I+D, Mariano Esquillor Gómez, 50018 Zaragoza, Spain. Hauptthemen laut MEDLINE: Enzyme Therapy, Nanostructures. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 293 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
In recent years, enzyme therapy strategies have rapidly evolved to catalyze essential biochemical reactions with therapeutic potential. These approaches hold particular promise in addressing rare genetic disorders, cancer treatment, neurodegenerative conditions, wound healing, inflammation management, and infectious disease control, among others. There are several primary reasons for the utilization of enzymes as therapeutics: their substrate specificity, their biological compatibility, and their ability to generate a high number of product molecules per enzyme unit. These features have encouraged their application in enzyme replacement therapy where the enzyme serves as the therapeutic agent to rectify abnormal metabolic and physiological processes, enzyme prodrug therapy where the enzyme initiates a clinical effect by activating prodrugs, and enzyme dynamic or starving therapy where the enzyme acts upon host substrate molecules. Currently, there are >20 commercialized products based on therapeutic enzymes, but approval rates are considerably lower than other biologicals. This has stimulated nanobiotechnology in the last years to develop nanoparticle-based solutions that integrate therapeutic enzymes. This approach aims to enhance stability, prevent rapid clearance, reduce immunogenicity, and even enable spatio-temporal activation of the therapeutic catalyst. This comprehensive review delves into emerging trends in the application of therapeutic enzymes, with a particular emphasis on the synergistic opportunities presented by incorporating enzymes into nanomaterials. Such integration holds the promise of enhancing existing therapies or even paving the way for innovative nanotherapeutic approaches.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC/Universidad de Zaragoza, c/ Edificio I+D, Mariano Esquillor Gómez, 50018 Zaragoza, Spain.
- Laboratorio de Biotecnología, Facultad de Ingeniería, Universidad ORT Uruguay, Mercedes 1237, 11100 Montevideo, Uruguay.
- Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC/Universidad de Zaragoza, c/ Edificio I+D, Mariano Esquillor Gómez, 50018 Zaragoza, Spain; Centro de Investigación Biomédica en Red de Bioingeniería, Biomateri…
Zitieren
APA
Torres-Herrero, B., Armenia, I., Ortiz, C., de la Fuente, J. M., Betancor, L., & Grazú, V. (2024). Opportunities for nanomaterials in enzyme therapy. Journal of Controlled Release, 372, 619-647. https://doi.org/10.1016/j.jconrel.2024.06.035
Vancouver
Torres-Herrero B, Armenia I, Ortiz C, de la Fuente JM, Betancor L, Grazú V. Opportunities for nanomaterials in enzyme therapy. Journal of Controlled Release. 2024;372:619-647. doi:10.1016/j.jconrel.2024.06.035
BibTeX
@article{TorresHerrero2024,
author = {Torres-Herrero, Beatriz and Armenia, Ilaria and Ortiz, Cecilia and de la Fuente, Jesús Martinez and Betancor, Lorena and Grazú, Valeria},
title = {Opportunities for nanomaterials in enzyme therapy},
journal = {Journal of Controlled Release},
year = {2024},
volume = {372},
pages = {619--647},
doi = {10.1016/j.jconrel.2024.06.035}
}
EUVIMED